These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 27574114)
1. Inhibition of nuclear factor kappaB proteins-platinated DNA interactions correlates with cytotoxic effectiveness of the platinum complexes. Brabec V; Kasparkova J; Kostrhunova H; Farrell NP Sci Rep; 2016 Aug; 6():28474. PubMed ID: 27574114 [TBL] [Abstract][Full Text] [Related]
2. Different affinity of nuclear factor-kappa B proteins to DNA modified by antitumor cisplatin and its clinically ineffective trans isomer. Kasparkova J; Thibault T; Kostrhunova H; Stepankova J; Vojtiskova M; Muchova T; Midoux P; Malinge JM; Brabec V FEBS J; 2014 Mar; 281(5):1393-1408. PubMed ID: 24418212 [TBL] [Abstract][Full Text] [Related]
3. Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin. Kasparkova J; Fojta M; Farrell N; Brabec V Nucleic Acids Res; 2004; 32(18):5546-52. PubMed ID: 15486204 [TBL] [Abstract][Full Text] [Related]
4. Energetics, conformation, and recognition of DNA duplexes containing a major adduct of an anticancer azolato-bridged dinuclear Pt(II) complex. Mlcouskova J; Malina J; Novohradsky V; Kasparkova J; Komeda S; Brabec V Biochim Biophys Acta; 2012 Oct; 1820(10):1502-11. PubMed ID: 22683702 [TBL] [Abstract][Full Text] [Related]
5. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. Kasparkova J; Pospisilova S; Brabec V J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA. Malina J; Natile G; Brabec V Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652 [TBL] [Abstract][Full Text] [Related]
7. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637 [TBL] [Abstract][Full Text] [Related]
8. Thermodynamic properties of duplex DNA containing a site-specific d(GpG) intrastrand crosslink formed by an antitumor dinuclear platinum complex. Hofr C; Farrell N; Brabec V Nucleic Acids Res; 2001 May; 29(10):2034-40. PubMed ID: 11353072 [TBL] [Abstract][Full Text] [Related]
9. Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand. Frybortova M; Novakova O; Stepankova J; Novohradsky V; Gibson D; Kasparkova J; Brabec V J Inorg Biochem; 2013 Sep; 126():46-54. PubMed ID: 23770803 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in multinuclear complexes as potential anticancer and DNA binding agents. Wang K; Gao E Anticancer Agents Med Chem; 2014 Jan; 14(1):147-69. PubMed ID: 23869783 [TBL] [Abstract][Full Text] [Related]
11. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Kasparkova J; Novakova O; Farrell N; Brabec V Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292 [TBL] [Abstract][Full Text] [Related]
12. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues. Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968 [TBL] [Abstract][Full Text] [Related]
13. Effect of geometric isomerism in dinuclear platinum antitumor complexes on DNA interstrand cross-linking. Kaspárková J; Nováková O; Vrána O; Farrell N; Brabec V Biochemistry; 1999 Aug; 38(34):10997-1005. PubMed ID: 10460154 [TBL] [Abstract][Full Text] [Related]
14. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899 [TBL] [Abstract][Full Text] [Related]
15. DNA interstrand cross-links of an antitumor trinuclear platinum(II) complex: thermodynamic analysis and chemical probing. Malina J; Farrell NP; Brabec V Chem Asian J; 2011 Jun; 6(6):1566-74. PubMed ID: 21557487 [TBL] [Abstract][Full Text] [Related]
16. DNA binding studies with cis-dichlorobis (5(6)-non/chlorosubstituted-2-hydroxymethyl-benzimidazole) platinum(II) complexes. Gümüş F; Algül O J Inorg Biochem; 1997 Oct; 68(1):71-4. PubMed ID: 9379182 [TBL] [Abstract][Full Text] [Related]
17. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. Kasparkova J; Farrell N; Brabec V J Biol Chem; 2000 May; 275(21):15789-98. PubMed ID: 10747955 [TBL] [Abstract][Full Text] [Related]
18. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. Pasheva EA; Ugrinova I; Spassovska NC; Pashev IG Int J Biochem Cell Biol; 2002 Jan; 34(1):87-92. PubMed ID: 11733188 [TBL] [Abstract][Full Text] [Related]